AtheroGenics ( AGIX) rose 14% as the company continued to recover from a big loss to start the week. On Monday, its shares tumbled roughly 60% after its heart disease drug failed to meet the main target of a phase III trial. The stock was recently adding 45 cents to $3.67.

Adams Respiratory Therapeutics ( ARXT) was also surging after the company said it has settled a patent lawsuit over a generic version of Mucinex with Mutual Pharmaceutical and United Research Laboratories. Recently, Adams was climbing $5.17, or 16.8%, to $36.01.

On the downside, Avalon Pharmaceuticals ( AVRX) dropped 5.1% after the drugmaker's fourth-quarter loss swelled from the same quarter in the previous year. The stock was off 24 cents at $4.48.

Elsewhere, JPMorgan reduced both GlaxoSmithKline ( GSK) and AstraZeneca ( AZN) to underweight from neutral. GlaxoSmithKline was off 1.4% at $55.44, and AstraZeneca was down 1.3% at $55.95.

Also on the move, ISIS Pharmaceuticals ( ISIS) was up 7.6% at $10.32. ImClone Systems ( IMCL) was rising 4.2% at $34. Nektar Therapeutics ( NKTR) was gaining 2.4% to $12.44.

Among decliners, Celgene ( CELG) was off 2.2% at $53.42. St. Jude Medical ( STJ) was recently down 1% to $37.99.

More from Investing

Eli Lilly Shares Jump After Dividend Boost, Robust 2019 Outlook

Eli Lilly Shares Jump After Dividend Boost, Robust 2019 Outlook

FedEx Falls Sharply After Cutting Profit Forecast

FedEx Falls Sharply After Cutting Profit Forecast

Micron Tumbles After Earnings Forecast Sparks Memory Demand Concerns

Micron Tumbles After Earnings Forecast Sparks Memory Demand Concerns

Jabil Stock Surges on Stellar First-Quarter Earnings

Jabil Stock Surges on Stellar First-Quarter Earnings

2019 Could Be a Great Year for Gold Miners

2019 Could Be a Great Year for Gold Miners